文献速递白血病

急性髓系白血病循环游离DNA与骨髓靶向测序对比

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

该研究对22例急性髓系白血病患者在诊断时和缓解后同步进行循环游离DNA与骨髓的靶向二代测序,共检测到39个独特体细胞突变,其中5个(13%)仅见于ccfDNA,15个(38%)仅见于骨髓。两种来源均检出的19个突变VAF一致性高(R2=0.849);仅单来源检出的突变VAF普遍较低,提示两法可能互补,且ccfDNA可发现骨髓未检出的临床相关突变并可能用于可测量残留病评估。

要点

  • ccfDNA与骨髓检出的突变不完全重叠,仅单来源检出者VAF多较低。
  • 两法均检出突变的VAF一致性高(R2=0.849),支持ccfDNA定量可靠性。
  • VAF<10%时两法均可能漏检,提示ccfDNA与骨髓应互补使用。

核心结论

  • ccfDNA测序可检出骨髓未发现的临床相关突变,并可能用于AML可测量残留病评估,但两法在低VAF时均会漏检,提示二者互补。

研究设计与样本

  • 对22例急性髓系白血病患者在诊断时和达到缓解后进行ccfDNA与骨髓的靶向二代测序,两平台共同测序28个基因。

主要发现

  • 共检测到39个独特体细胞突变,5个(13%)仅见于ccfDNA,15个(38%)仅见于骨髓。
  • 两法均检出的19个突变VAF一致性高(R2=0.849)。
  • 仅单来源检出的突变VAF一般低于两法均检出者,提示可能漏检小亚克隆。
  • 3例患者在缓解期ccfDNA检出新的或持续的白血病相关突变,似预示明显复发。

关键数值与推荐

  • VAF<10%时ccfDNA和骨髓分析均可能漏检突变。

临床怎么用

  • 在AML突变评估与残留病监测中可考虑ccfDNA与骨髓互补使用,尤其关注ccfDNA可发现的骨髓未检出突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Circulating cell-free DNA (ccfDNA) allows for noninvasive peripheral blood sampling of cancer-associated mutations and has established clinical utility in several solid tumors. We performed targeted next-generation sequencing of ccfDNA and bone marrow at the time of diagnosis and after achieving remission in 22 patients with acute myeloid leukemia (AML). Among 28 genes sequenced by both platforms, a total of 39 unique somatic mutations were detected. Five mutations (13%) were detected only in ccfDNA, and 15 (38%) were detected only in bone marrow. Among the 19 mutations detected in both sources, the concordance of variant allelic frequency (VAF) assessment by both methods was high (R2 = 0.849). Mutations detected in only 1 source generally had lower VAF than those detected in both sources, suggesting that either method may miss small subclonal populations. In 3 patients, sequencing of ccfDNA detected new or persistent leukemia-associated mutations during remission that appeared to herald overt relapse. Overall, this study demonstrates that sequencing of ccfDNA in patients with AML can identify clinically relevant mutations not detected in the bone marrow and may play a role in the assessment of measurable residual disease. However, mutations were missed by both ccfDNA and bone marrow analyses, particularly when the VAF was <10%, suggesting that ccfDNA and bone marrow may be complementary in the assessment and monitoring of patients with AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Short NJ, Patel KP, Albitar M, et al. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020. PMID: 32324887. doi:10.1182/bloodadvances.2019001156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。